The No Risk
Blood Based
Biopsy
The Problem Statement
Cancer diagnosis is often through biopsies which are invasive and may not be completely accurate. There is often a lot of anxiety, pain, risk and costs associated with invasive biopsies for the diagnosis of cancer.
Usual Tissue Biopsy/FNAC
- Invasive, need tissue and is ultimately expensive
- Needs to be performed only in a hospital environment
- Can be painful, may need stitches and leave scars
- Carries the innate risk of tumor cell ‘seeding’
- Can be risky for organs like lung, liver, pancreas
- May be impacted by tumor heterogeneity
- Serial/sequential biopsies are challenging
- May not be viable if the primary tumor is not easily visualised
Trublood® is a revolutionary non-invasive, cost-effective, safe and accurate blood test that can be used in most suspected cases of solid tumors and brain tumors instead of an invasive biopsy. The test is conducted on peripheral blood and involves a simple blood draw. The results are available in 10-12 days.
- To triage symptomatic individuals who have been advised an invasive tissue biopsy to check for malignancy
- Patients where an invasive biopsy has been inconclusive or inconsistent with clinical observations
- Suspected metastatic relapse to rule out a new primary
Key Benefits of Trublood®
- Totally non-invasive and is ultimately less expensive
- No hospitalization
- No pain, no stitches, no scars
- No risk of injury to any organ
- Provides ‘Real-Time’ data and covers all active sites
- Can be performed as often as necessary
- Viable even if primary/metastasis are undetectable
Large clinical studies to back up performance
The performance of Trublood® test is supported by rigorous clinical studies with more than 40,000 participants representing diverse populations.1,2
40,000+
Participants
We’re here to assist you
If you have any questions or want to learn more, please contact us or visit our FAQs.
1Akolkar et al, Circulating ensembles of tumor-associated cells: A redoubtable new systemic hallmark of cancer, https://doi.org/10.1002/ijc.32815
2Ranade et al, Hallmark Circulating Tumor-Associated Cell Clusters Signify 230 Times Higher One-Year Cancer Risk. Cancer Prev Res (Phila). 2021 Jan;14(1):11-16. doi: 10.1158/1940-6207.CAPR-20-0322. Epub 2020 Sep 21. PMID: 32958586.
2Ranade et al, Hallmark Circulating Tumor-Associated Cell Clusters Signify 230 Times Higher One-Year Cancer Risk. Cancer Prev Res (Phila). 2021 Jan;14(1):11-16. doi: 10.1158/1940-6207.CAPR-20-0322. Epub 2020 Sep 21. PMID: 32958586.